Briobacept
Briobacept (BR 3FC) is a recombinant glucoprotein, consists of 2 molecules from the BLyS receptor (BR3) and a Fc domain of human IgG1. Briobacept selectively targets to BLyS (BAFF), induces B cells apoptosis. Briobacept can be used in studies of rheumatoid arthritis (RA) [1][2].
Product Specifications
CAS Number
869881-54-9
Product Name Alternative
BR 3FC
UNSPSC
12352203
Target
ADC Antibody
Type
Inhibitory Antibodies
Related Pathways
Antibody-drug Conjugate/ADC Related
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/briobacept.html
Purity
97.66
Solubility
10 mM in DMSO
Smiles
[Briobacept]
Molecular Weight
(65.75 kDa)
References & Citations
[1]Sifuentes Giraldo WA, et al. New targets in systemic lupus (part 2/2) . Reumatol Clin. 2012 Sep-Oct;8 (5) :263-9. |[2]Liu Yunjie, et al. Research progress on the pathogenesis and drug targeting therapy of B lymphocyte stimulator-induced rheumatoid arthritis. 2011;22 (33) :3152-3154. |[3]La Cava A. Targeting B cells with biologics in systemic lupus erythematosus. Expert Opin Biol Ther. 2010 Nov;10 (11) :1555-61. |[4]Kayagaki N, et al. BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2. Immunity. 2002 Oct;17 (4) :515-24.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
